Key Dates

Related Announcements

PAR-23-102 - Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)

Issued by

National Institute of Mental Health (NIMH)

Purpose

This notice announces changes to the locus of review of Notice of Funding Opportunity (NOFO) PAR-23-102  “Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)”.

The following sections of PAR-23-102 have been modified to reflect revisions to Locus of Review:

Currently Reads:

Section V. Application Review Information

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMH, in accordance with NIH peer review policy and procedures, using the stated review criteria.  Assignment to a Scientific Review Group will be shown in the eRA Commons.

Modified to Read (changes shown in bold italics):

Section V. Application Review Information

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria.  Assignment to a Scientific Review Group will be shown in the eRA Commons.

All other aspects of this NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Laura M. Rowland, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-480-8335
Email: laura.rowland@nih.gov